CAR T-Cell Therapy ee Shiinaha
Daaweynta CAR T Cell ee Shiinaha is progressing remarkably and has the potential to revolutionize cancer treatment. China is now a pioneer in this industry thanks to its strong regulatory framework and research infrastructure, which have fueled its development.
CAR T Cell therapy in China is available for 40,000 USD. Furthermore, China’s enormous patient population offers a special benefit for carrying out tijaabada caafimaadka and compiling data.
China’s efforts are influencing the future of daawada saxda ah iyo siinta rajo cusub bukaanada kansarka adduunka oo dhan sida CAR T-cell daaweynta.
Maxaa ka dhigaya CAR T daawaynta unugyada Shiinaha mid gaar ah?
CAR T-cell therapy in China is a significant advancement in cancer treatment and has given patients who previously had few options new hope. This innovative therapy has gained prominence in China, where over 700 ongoing tijaabada caafimaadka waxay sahamiyaan siyaabaha kor loogu qaado waxtarkeeda iyo badbaadada.
China has emerged as a pioneer in this field, showcasing a strong dedication to medical research and advanced patient care. The science behind CAR T Daaweynta unugyada for cancer in China involves modifying a patient’s own unugyada difaaca to recognize and attack cancer cells. This is achieved through genetic engineering, where the patient’s T cells are equipped with a chimeric antigen receptor (CAR) that targets cancer-specific borotiinada. T cells are removed from the patient, genetically modified in a laboratory, and then infused back into the patient’s body to attack kansarka.
Daaweynta unugyada CAR T for cancer in china has been effective in treating a variety of cancers, and continuing research continues to refine and broaden its applicability. With commercial applications such as Yescarta and Relma-cel, the future of CAR T-cell treatment in China is bright, with major market growth projected and domestic players making substantial breakthroughs. The journey from clinical trials to commercial applications reflects the dedication to advancing medical science for the benefit of cancer patients in China.
Daawaynta Unugyada CAR T ee Shiinaha ayaa Maraykanka kaga sarreeya Xalka Kansarka!
Sidee Shiinuhu ugu Sarreeyaa Tijaabada Caafimaadka?
Laga bilaabo Janaayo 2024, waxaa jira in ka badan 700 oo tijaabo caafimaad ah oo hadda ka socda isbitaallo kala duwan oo Shiinaha ku yaal kuwaas oo diiradda saaraya horumarinta daawaynta unugyada CAR T. Tan iyo 2017 dawladda Shiinaha waxay si weyn u maalgalisay booska bayoolajiga, natiijaduna waa mid xad dhaaf ah. Shiinuhu wuxuu u soo baxay inuu yahay cilmi-baaris cilmi-baariseed oo awood leh, gaar ahaan goobta-goynta ee daaweynta unugyada CAR-T ee kansarka ee Shiinaha. Daraasadahan caafimaad, oo ay sameeyeen machadyo caan ah, ayaa horumar la taaban karo ka samaynaya daaweynta noocyada kala duwan ee kansarka. CAR T daawaynta unugyada leukemia ee Shiinaha, CAR T Therapy ee lymphoma iyo BCMA ku salaysan CAR T daawaynta unugga ee myeloma badan ee Shiinaha waa noocyo waaweyn oo jawaabo togan ka helaya tijaabooyinka.
Tusaale ahaan, Cisbitaalka Kansarka ee Jaamacadda Peking ee Beijing, Shiinaha waxay muujisay natiijooyin aad u wanaagsan daawaynta soo noqnoqota ama adkaysiga u leh lymfoblastic leukemia (ALL) oo leh unugyo CAR-T, oo siinaya khad nololeed bukaannada leh xulashooyin xaddidan.
Diiradadu maaha kaliya kansarka dhiiga; Shiinaha ayaa sidoo kale eegaya daaweynta unugyada CAR-T ee burooyinka adag, kuwaas oo markii hore ay adkeyd in la daweeyo. Si looga gudbo xaaladaha adag ee difaaca jirka ee la xakameeyey ee ku jira burooyinka, xeelado caqli badan ayaa la adeegsadaa si loo hagaajiyo waxtarka unugyada CAR-T.
Wadashaqeynta caalamiga ah ayaa door muhiim ah ka ciyaarta guusha Shiinaha, iyadoo cilmi-baarayaasha Shiinuhu ay iska kaashanayaan caalamka oo dhan si ay khibradaha isku weydaarsadaan. Tallaabadani waxay wax ka beddeli kartaa CAR T Shiinaha, iyada oo bixisa beddel habboon oo kharash-ool ah.
Waa maxay Baaxadda Daawaynta CAR-T ee Shiinaha?
Isticmaalka daawaynta unugyada T-cell ee chimeric antigen receptor (CAR) ee daaweynta malignancies hematological ayaa si cajiib ah waxtar leh. Codsiga daawaynta CAR T-cell waxay ku kortay Shiinaha sagaalkii sano ee la soo dhaafay.
Daraasadihii ugu horreeyay ee CAR T ee bukaan-socodka ayaa bilaabmay 2013, iyo 2017 waxaa jiray tijaabooyinka bukaan-socodka ee unugyada CAR T ka badan sidii hore. Wax yar ka dib, Shiinuhu wuxuu ku dhawaaqay inuu bixin doono wadarta US $ 237 bilyan maalgelinta ganacsiyada daaweynta unugyada sanadka 2021, taas oo ka dhigan koror aad u weyn tirada tijaabooyinka caafimaad iyo mashaariicda cilmi-baarista aasaasiga ah ee ku lug leh unugyada CAR T.
Taageerada xooggan ee dawladda, qulqulka lacagta, baahida bukaanka sare, nidaam daryeel caafimaad oo gaar ah, iyo dadaalka dhakhaatiirta Shiinaha iyo saynisyahannada ayaa dhammaantood gacan ka geystay kor u kaca weyn ee dhaqdhaqaaqa Shiinaha.
Habka daaweynta CAR T-Cell
CAR T Cell Therapy for multiple myeloma in China, iyo sidoo kale noocyada kale ee kansarka dhiigga, waa nooc ka mid ah immunotherapy horumarsan oo ay ku jiraan dib u habaynta unugyada difaaca bukaanka si ay u beegsadaan iyo baabi'inta unugyada kansarka. Habka unugga CAR T wuxuu caadi ahaan ku lug leeyahay dhowr tillaabo oo muhiim ah:
Ururinta Unugyada (Apheresis):
Dhaqanka ururinta unugyada T ee bukaanka, oo ah nooca unugyada difaaca, waxaa loo yaqaannaa apheresis. Inta lagu jiro apheresis, dhiig ayaa laga soo ururiyaa bukaanka iyo mishiinka ayaa kala sooca unugyada T. Dhiiga haray ayaa markaas lagu soo celiyaa jirka bukaanka. Unugyada T waxaa laga soo ururiyaa dhiigga iyadoo la isticmaalayo tuubo la geliyo xididka cududda. Tani waxay qaadataa dhowr saacadood.
Beddelka Hiddaha:
Unugyada T-da waxaa wax laga beddelay shaybaarka si ay u muujiyaan Chimeric Antigen Receptor (CAR) oo korkooda ah. CAR waxaa loo qorsheeyay in lagu aqoonsado borotiinno gaar ah, ama antigens, oo laga helo dusha unugyada kansarka.
Balaadhinta Unugyada:
Unugyada T-da ee hiddo-wadaha la beddelay ayaa markaa la beeraa oo la badiyo, taasoo keentay in tiro badan oo unugyada CAR T ah. Habkani waxa uu hubinayaa in ay jiraan unugyo T la beddelay oo ku filan oo loo heli karo daaweyn waxtar leh.
Qaboojinta (Lymphodepletion):
Bukaannada waxaa caadi ahaan lagu daweeyaa daawaynta qaboojinta ka hor faleebada CAR T-cell, taas oo ay ku jiri karto kimoterabi-yar ama shucaac. Qaboojintani waxay gacan ka geysataa abuurista jawi ay unugyada CAR T ee dhowaan la galiyey ku bami karaan oo ay ka shaqayn karaan gudaha jidhka bukaanka.
Faleebo ee unugyada T-CAR:
Marka la diyaariyo, unugyada CAR T ayaa dib loogu duraa dhiigga bukaanka iyada oo loo marayo faleebo. Unugyada CAR T ee la geliyey ayaa markaa ku wareegaya jirka oo dhan, iyagoo raadinaya oo ku xiraya unugyada kansarka ee muujinaya antigen-ka la beegsaday.
Beegsiga iyo Dilka Unugyada Kansarka:
Marka unug CAR T ahi uu taabto unug kansar oo ka kooban antigen-ka habboon, waxay ku xidhan tahay unugga kansarka. Is dhexgalkani waxa uu hawlgeliyaa unugga CAR T, isaga oo keenaya in uu sii daayo molecules dila unugyada kansarka.
Kormeerka Jawaabta:
Bukaanka si dhow ayaa loola socdaa calaamad kasta oo jawaab celin ah, oo ay ku jirto dhimista xajmiga burooyinka. Guusha daaweynta CAR T-cell waxaa lagu qiimeeyaa iyadoo la adeegsanayo sawir-qaadid iyo shaybaar kala duwan.
Maareynta Saamaynta Dhinacyada:
Bukaanjiifka qaar ayaa laga yaabaa inay qabaan xanuunka sii deynta cytokine (CRS) ama neurotoxicity, kuwaas oo ay si dhow ula socdaan khabiirada daryeelka caafimaadka.
Sida Loo Codsado CAR T-Cell Therapy gudaha Shiinaha?
Soo dir warbixinnadaada
U soo dir warbixinnada soo socda oo ay ku jiraan soo koobid caafimaad, warbixinadii ugu dambeeyay ee dhiiga, Biopsy, Baaritaanka PET ee ugu dambeeyay, dhuuxa lafta ka-qaadista (Haddii la heli karo) info@cancerfax.com ama WhatsApp iyaga oo ah +1-213 789-56-55
Qiimaynta & Ra'yiga
Marka kooxdayadu ay hesho warbixinnadaada caafimaad, waanu falanqeyneynaa waxaana u direynaa isbitaalada fulinaya daaweynta CAR T-cell ee leh nooca kansarka iyo calaamadeeyaha. Waxaan u dirnaa warbixinnada takhasuska ay khuseyso oo aan helno ra'yigiisa. Waxa kale oo aanu cusbitaalka ka helnaa qiyaaso ku saabsan daawaynta dhamaystiran.
Fiisaha caafimaadka iyo safarka
Marka aad go'aansato inaad booqato daawaynta, waxaanu kuu diyaarinaynaa warqad fiisaha caafimaadka iyo dukumeentiyada kale ee lagama maarmaanka ah ee isbitaalka. Marka fiisuhu diyaar yahay waxaanu kaa caawinaynaa oo ku hagaya isu diyaarinta safarka iyo tigidhada duulimaadka.
Daawaynta iyo dabagalka
Wakiilkayagu wuxuu kuu qabanqaabin doonaa ballan dhakhtar oo wuxuu kuu dhammaystiri doonaa habraacyada diiwaangelinta lagama maarmaanka ah. Waxa kale oo uu kaa caawin doonaa gelitaankaaga cusbitaalka iyo caawimada iyo taageerada degaanka ee kale ee loo baahan yahay. Ka dib markii daawadu dhammaato waxa aanu kuu diyaarin doonaa la-talintaada dabagalka ah ee dhakhtarka daweynta.
Waa maxay sababta Shiinuhu u yahay doorashada ugu fiican?
Tijaabooyin Caafimaad & Cilmi-baaris Hormar ah
In ka badan 700 tijaabo caafimaad oo socda oo ku saabsan daawaynta CAR T-Cell ee kansarka ee Shiinaha ayaa gaadhay horumarro waaweyn. Daawaynta cusub ee CAR T-cell ayaa si firfircoon loo sameeyay oo ay tijaabiyeen cilmi-baarayaasha Shiinaha iyo machadyada caafimaadka, iyada oo diiradda la saarayo labadaba burooyinka adag iyo cudurrada dhiigbaxa. Marka la eego horumarinta daawaynta unugyada CAR T, Shiinuhu wuxuu ku jiray feejignaanta, tijaabooyin badan oo kiliinig ah ayaa ka dhacaya halkaas. Sababtaas awgeed, bukaannada raadinaya inay helaan horumarradii ugu dambeeyay ee daaweynta unugyada CAR T waxay u heli karaan Shiinaha inuu yahay beddel soo jiidasho leh.
Qiimaha Iyo Helitaanka
CAR T-Cell therapy Qiimaha ee Shiinaha aad ayuu uga hooseeyaa kan wadamada sida US, UK, Australia, Japan, Kuuriya, iyo Singapore. Daaweynta CAR T-Cell ee Shiinaha waxay ku kici kartaa kaliya $60,000. Shiinuhu wuxuu leeyahay helitaan aad u sarreeya oo ah daawaynta unugyada CAR T ee kansarka Shiinaha. Waxaa laga yaabaa inay jiraan waqtiyo sugitaan oo daweyn gaaban hadda ka dib markii tas-hiilaad caafimaad oo badan oo Shiinaha ah ay heleen oggolaansho sharciyeed si ay u bixiyaan daaweynta unugyada CAR T. Intaa waxaa dheer, daawaynta unugyada CAR T ayaa inta badan ka qaalisan Shiinaha marka loo eego meelaha kale, sida Mareykanka. Cunsurkani waxa uu si gaar ah muhiim ugu yahay dadka raadinaya doorashooyin daawaynta la awoodi karo.
Khibrad Iyo Waayo Aragnimo
Sababo la xiriira ka qaybqaadashada tijaabooyinka iyo daawaynta badan ee kiliinikada, Shiinuhu waxa uu horumariyay aqoon iyo waayo-aragnimo aad u badan oo ku saabsan bixinta daawaynta unugyada CAR T ee leukemia-da ee Shiinaha khubarada caafimaadka Shiinaha ayaa horumariyay aqoontooda dhibaatooyinka daaweynta unugyada CAR T iyo awooddooda maareeyaan si ay u hagaajiyaan natiijooyinka bukaanka. Shiinuhu wuxuu bixiyaa daryeel caafimaad oo tayo sare leh iyada oo ay ugu mahadcelinayso dadkeeda tirada badan ee buka, kaabayaasha taageerada, iyo aqoonta la ururiyay ee daawaynta unugyada CAR T ee kansarka Shiinaha.
Shirkadaha Maraykanka oo Iskaashanaya Shirkadaha Shiinaha
Sannadihii u dambeeyay, ganacsiyada Maraykanku waxay bilaabeen inay la shaqeeyaan dhiggooda Shiinaha si ay u horumariyaan daawooyinka unugyada CAR T. Tusaale ahaan. 2015, WuXi AppTec, oo ah hay'ad cilmi baaris qandaraas oo Shiinees ah (CRO), iyo Juno Therapeutics, ganacsi biopharmaceutical fadhigeedu yahay Mareykanka, ayaa si istiraatiji ah iska kaashaday. Shirkadda Shiineeska ah ee biopharmaceutical Cellular Biomedicine Group waxay la shaqeysay shirkadda Maraykanka ee Celgene, oo hadda ah qayb ka mid ah Bristol-Myers Squibb. Iskaashi caalami ah iyo heshiis shati ayaa dhex maray Janssen Biotech, shirkad dawooyin ah oo ay leedahay Johnson & Johnson, iyo Legend Biotech, oo ah ganacsi ka shaqeeya Shiinaha iyo Mareykanka labadaba.
Dhakhaatiirta ugu sareysa ee CAR-T Therapy gudaha Shiinaha
Qaado ra'yi labaad oo khabiir ah oo ku saabsan faleebo daawaynta CAR T-Cell ee cilmi-baarayaasha ugu fiican Shiinaha.
Prof. Peihua Peggy Lu, (MD)
Madaxa Fulinta Caafimaadka ee Isbitaalka Lu Daopei, Beijing, Shiinaha, Khibrad: 27 Sano
Dr Zhao Defeng, (MD)
Agaasimaha, Waaxda Hematology, Isbitaalka Gobroad ee Beijing, Khibrad: 24 Sano
Dr. Zhao Defeng waa Agaasimaha Waaxda Dhiigbaxa ee Gaobo Medical (Hematology) Xarunta Cilmi-baarista ee Beijing, Isbitaalka Gaobo Boren ee Beijing, oo ku takhasusay caafimaadka guud ee Ward Sagaal. Waxa uu haystaa jagada Associate Chief Physician oo uu shahaado Master ah ka qaatay Jaamacadda Caafimaadka ee Labaad. Dr. Defeng waxa uu khibrad u leeyahay in ka badan 1000 bukaan ah oo maamula daawaynta CAR T-cell waxana uu leeyahay in ka badan 23 tijaabo caafimaad oo socda. Waxaa loo arkaa mid ka mid ah Dhakhaatiirta ugu fiican ee daaweynta CAR T-cell ee Shiinaha.
Cisbitaalada ugu Sareeya ee loogu talagalay CAR T Daaweynta Shiinaha
Isbitaalka Kansarka ee Jaamacadda Peking
Habka cusub ee difaaca jirka ee loo yaqaan CAR T-cell therapy ayaa muujisay ballanqaad aan caadi ahayn oo ku saabsan daaweynta cudurrada kala duwan. Beijing, Cusbitaalka Kansarka ee Jaamacadda Peking ee Shiinaha ayaa noqday hormuudka caalamiga ah ee horumarinta daaweynta CAR T-cell. Iyaga oo gacan ka helaya kooxdooda cilmi-nafsiyeedka badan, oo ka kooban dhakhaatiirta kansarka, dhakhaatiirta difaaca jirka, iyo hidde-yaqaannada, daaweynta kansarka shakhsi ahaaneed ayaa si weyn u horumartay. Cisbitaalka Kansarka ee Jaamacadda Peking ayaa natiijooyin fiican ka helay bukaannada qaba cudurrada dhiig-baxa iyagoo beddelaya unugyada T bukaannada si ay u muujiyaan reseptors-ka antigen-ka (CARs). Daawayntan goynta ahi waxay siinaysaa bukaanada kansarka rajo cusub iyada oo isbedelaysa qaybta kansarka iyo kor u qaadista heerka badbaadada.
Beijing Gobroad Boren Hospital
Khabiirka caanka ah wuxuu leeyahay soddon sano oo waayo-aragnimo caafimaad iyo shaybaar gudaha ah oo ballaaran, isagoo si gaar ah diiradda u saaray qaybta dhiigbaxa. Waaxdu waxay bixisaa adeegyo baaritaan iyo daweyn oo kala duwan oo loogu talagalay cudurrada saameeya nidaamka dhiigbaxa, sida Multiple myeloma, leukemia, lymphoma, thalassaemia, cilladaha xinjirowga dhiigga, iyo burooyinka hematological. Waxay ku takhasustay qorshayaasha daawaynta ee gaarka ah iyo ogaanshaha isku dhafan ee cudurrada dhiigga. Ikhtiyaarada daawaynta ee burooyinka dhiiga waxaa ka mid ah daawaynta kiimikaad, immunotherapy, daawayn la bar tilmaameedsado, demethylation, iyo radiotherapy. Intaa waxaa dheer, si loo hubiyo badbaadada iyo waxtarka isticmaalka daawada, shaqaalaheena caafimaadku waxay sidoo kale wax ka beddelaan qiyaasaha iyada oo la raacayo sifooyinka dheef-shiid kiimikaadka daroogada iyo la socodka feejignaanta daroogada.
Isbitaalka Lu-Daopei
Beijing, Cusbitaalka Lu Daopei ee Shiinaha ayaa si weyn u horumariyay goobta daaweynta CAR T-cell. Isbitaalka Lu Daopei, oo mudnaan sare siiya daaweynta kansarka iyo cilmi baarista, ayaa safka hore kaga jirtay codsashada daawaynta CAR T-cell si loogu daweeyo cudurrada dhiigbaxa. Dhakhaatiirta Oncologists, Immunologists, iyo geneticists kooxdooda waxaa ka go'an in ay dhamaystiraan tijaabooyinka kiliinikada iyo abuuritaanka daaweynta CAR T-cell ee bukaanka u gaarka ah. Isbitaalka Lu Daopei wuxuu arkay horumar dhiirigelin leh oo ku saabsan natiijooyinka bukaan-socodka iyo heerka badbaadada sababtoo ah aqoontiisa iyo tas-hiilaadkiisa ugu sarreeya. Shaqadoodu waxay sii wadaan inay saameeyaan sida kansarka loo daweeyo, taasoo u furaysa fursado cusub bukaanada u baahan rajo. Ilaa hadda, waxay sheeganayaan inay sameeyeen in ka badan 1000 faleebo daawaynta CAR T-Cell ah.
Cusbitaalka ugu horreeya ee ku xidhan, Dugsiga Caafimaadka ee Jaamacadda Zhejiang, Hangzhou
Isbitaalka ugu horreeya ee ku xiran, Dugsiga Caafimaadka ee Jaamacadda Zhejiang waxaa la aasaasay 1947. Waa cusbitaalka ugu horreeya ee Jaamacadda Zhejiang, dufcaddii ugu horreysay ee machadyada si loo dhiso xarumo caafimaad oo heer qaran ah "heer sare", Xarunta Caafimaadka Qaranka ee Cudurrada Infekshinka ah, Hay'adda Hoggaaminta Si loo dhiso heerka qaran ee Co
Cusbitaalka ugu horreeya ee ku xidhan, bogga dugsiga caafimaadka ee jaamacadda Zhejiang
Isbitaalka ugu horeeya ee ku xiran Jaamacadda Zhengzhou
Dhinaca daaweynta CAR T-cell, Isbitaalka ugu horreeya ee ku xiran Jaamacadda Zhengzhou, oo ku yaal Zhengzhou, Shiinaha, wuxuu noqday urur si fiican loo yaqaan. Isbitaalku waxa uu sameeyay horumar laxaad leh oo uu ku kordhinayo awooda daawaynta unugyada CAR T-cell ee bukaanada isaga oo xooga saaraya daawaynta kansarka ee jeex jeexan. Dhakhaatiirta Oncologists, Immunologists, geneticists, iyo xubno kale oo ka mid ah shaqaalahooda caafimaadka ee kala duwan ayaa dhamaantood si firfircoon uga qayb qaatay daraasadaha iyo tijaabooyinka kiliinikada. Xaruntu waxa ay dawaysay xumaanta dhiig-baxa guulo la yaab leh iyada oo ay ugu wacan tahay isticmaalka daawaynta unugyada CAR T-cell. Sida daawaynta kansarka ee shakhsi ahaaneed ay horumarayso, Isbitaalka ugu horreeya ee ku xiran Jaamacadda Zhengzhou ayaa safka hore kaga jira, isagoo bukaannada siinaya rajo cusub iyo nolol tayo wanaagsan leh.
CAR T-Cell therapy Qiimaha ee Shiinaha
Aynu si qoto dheer u eegno kharashka Daaweynta unugyada CAR-T ee Shiinaha. Waxay caadi ahaan u dhaxaysaa $45,000 ilaa $80,000. Qiimaha FUCASO (daaweynta CAR T-Cell ku salaysan ee BCMA ee myeloma badan) waxay ku kacaysaa ilaa $200,000 USD. Laakiin maskaxda ku hay in kuwani yihiin qiyaaso qallafsan oo keliya, iyo kharashka saxda ah wuxuu ku xiran yahay dhowr arrimood. Nooca daawaynta CAR-T, kakanaanta daawaynta, kharashyada cisbitaalka, daryeelka dheeraadka ah, iyo ogaanshaha ayaa dhamaantood saamayn kara kharashka ugu dambeeya. Maskaxda ku hay in tirooyinkani ay isbedeli karaan iyadoo lagu salaynayo xaaladaada caafimaad. Si aad gacan uga geysato maaraynta kharashaadkan, waa inaad la tashataa kooxdaada daryeelka caafimaadka. Waxay ku siin karaan macluumaad gaar ah oo dheeraad ah. Waa inaad sidoo kale hubisaa in caymiskaagu uu daboolayo ama haddii wax barnaamijyo gargaar dhaqaale ah jiraan. Tani waxay kuu ogolaaneysaa inaad sameyso go'aamada ugu fiican labadaba daaweyntaada iyo miisaaniyadaada.
Waa maxay CAR T-Cell Therapy?
Chimeric antigen reseptor T-cell therapy, oo inta badan loo yaqaan CAR T-cell therapy, waa immunotherapy-jabin ah oo gebi ahaanba beddelay habka loo daweeyo kansarka. Waxay siisaa bukaanada qaba kansarrada qaarkood rajo oo markii hore loo arki jiray inay yihiin kuwo aan la daweyn karin ama leh dhowr dawo oo daaweyn ah.
Daawadu waxay ka kooban tahay isticmaalka unugyada difaaca jirka ee bukaanka - si gaar ah, unugyada T-iyo shaybaadhka wax ka beddelka iyaga si kor loogu qaado awooddooda si ay u ogaadaan oo ay u burburiyaan unugyada kansarka. Si taas loo sameeyo, unugyada T-da waxa la siiyaa reseptor-ka-kimeric antigen (CAR), kaas oo siinaya awood ay ku beegsadaan borotiinno gaar ah, ama antigens, oogada unugyada kansarka.
Unugyada T ee bukaanka ayaa marka hore laga saaraa, ka dibna si hidde ahaan wax looga beddelo si ay u muujiyaan CAR. Shaybaadhka, unugyadan la beddelay ayaa la badiyo si ay u soo saaraan tiro badan oo ah unugyada CAR T, kuwaas oo dib loogu celiyo dhiigga bukaanka.
Isla marka ay gudaha jidhka ku jiraan, unugyada CAR T waxay helayaan unugyo kansar oo muujiya antigen-ka la rabo, ku dheggan, oo kiciya jawaab celin difaac oo xooggan. Unugyada CAR T ee la hawlgeliyay way bataan oo waxay weerar ku qaadaan unugyada kansarka, iyaga oo dila.
Sidee buu u shaqeeyaa CAR T-Cell Therapy?
Marka loo isticmaalo daawaynta cudurrada dhiigga qaarkood sida leukemia ba'an oo ba'an (ALL) iyo noocyo gaar ah oo lymphoma ah, daawaynta unugga CAR T ee lymphoma ee Shiinaha waxay muujisay natiijooyin aan caadi ahayn. Waxay soo saartay heerar jawaab celin oo muuqda iyo bukaannada qaarkood, xitaa cafisyo waara.
Daawaynta CAR T-cell, si kastaba ha ahaatee, waa hab daawayn casri ah oo gaar ah oo laga yaabo inay leedahay khataro iyo saamayn xun. Cytokine release syndrome (CRS), falcelin difaaceed baahsan oo ka dhalan karta calaamado hargab oo kale ah iyo, xaaladaha daran, xubnaha oo fashilma, waxaa laga yaabaa inay la kulmaan dadka qaarkood. Waxa kale oo jiray warbixino ku saabsan saamaynta xun ee neerfaha, si kastaba ha ahaatee inta badan waa la daweyn karaa.
Iyadoo ay jiraan dhibaatooyinkan, daaweynta CAR T-cell waa horumar la taaban karo oo laga gaaray la dagaallanka kansarka waxayna muujineysaa karti weyn mustaqbalka. Daraasadaha hadda jira waxay diiradda saarayaan kor u qaadista waxtarkeeda iyo astaanta badbaadada iyo sidoo kale fidinta isticmaalkeeda noocyada kansarka ee kala duwan. Daaweynta CAR T-cell waxay bedeli kartaa wejiga daaweynta kansarka waxayna siin kartaa bukaannada meel kasta oo ay joogaan rajo cusub oo horumar dheeraad ah leh.
Daaweynta noocaan ah waxay ku lug leedahay wax ka beddelka unugyada T-da ee bukaanka, nooca unugyada difaaca, ee shaybaarka si ay u xidhaan una dilaan unugyada kansarka. Tuubbadu waxay dhiigga ka soo qaadaa xididka cududda bukaanka oo gaynaysa aaladda apheresis (aan la muujin), kaas oo soo saara unugyada dhiigga cad, oo ay ku jiraan unugyada T, oo ku soo celisa dhiigga soo hadhay bukaanka.
Unugyada T ayaa markaa si hidde ahaan wax looga beddelay shaybaarka si ay ugu jiraan hidda-wadaha loogu talagalay soo-qabeyaal gaar ah oo loo yaqaanno reseptor-ka antigen-ka (CAR). Unugyada CAR T waxay ku bataan shaybaadhka ka hor inta aan la gelin bukaanka tiro badan. Antigen-ka unugyada kansarka waxaa aqoonsan kara unugyada CAR T, ka dibna dila unugyada kansarka.
Noocee Kaansarka Ayaa Lagu Daweyn Karaa CAR-T Cell Therapy?
Kaliya bukaanada qaba kansarka qanjirka 'B-cell' ee Hodgkin's ama lymphoblastic leukemia ba'an ee carruurta kuwaas oo horey u tijaabiyey laba daawaynta caadiga ah ee aan guulaysan ayaa hadda isticmaali kara alaabada daaweynta CAR T-cell ee helay oggolaanshaha FDA. Si kastaba ha ahaatee, daaweynta CAR T-cell ayaa hadda lagu tijaabiyay daraasadaha kiliinikada sida daawaynta safka koowaad ama labaad ee lymphoma qaangaarka iyo kansarka carruurta ee lymphoblastic leukemia. Dhawaan, qaar ka mid ah daraasadaha ayaa muujiyay guulo cajiib ah kiisaska burooyinka adag sida glioblastoma, gliomas, kansarka beerka, kansarka sambabada, kansarka GI, kansarka ganaca, iyo kansarka afka.
Tani waxay ka dhigan tahay horumar la taaban karo oo laga sameeyay maaraynta leukemia iyo lymphoma B-cell. Intaa waxa dheer, waxa ay rajo gelinaysaa kuwa hore loo saadaaliyay in noloshooda ay ku jirto lix bilood oo keliya. Hadda oo aanu aqoonsannay hababka wax-iska-caabbinta oo aanu abuurnay farsamooyin badan oo lagula dagaallamo, mustaqbalka waxa uu u muuqdaa mid aad u rajo badan.
Kala xidhiidh bixiyeyaashayada daryeelka caafimaadka ee khibradda sare leh halkan Faa'iidada Kansarka la tashi bilaash ah si loo sameeyo qorshe daryeel oo ku habboon baahiyahaaga daryeelka caafimaadka. Fadlan u soo dir warbixinnadaada caafimaad info@cancerfax.com ama WhatsApp at + 1 213 789 56 55.
Waa maxay Faa'iidooyinka Daaweynta Unugyada CAR-T?
Faa'iidada ugu weyni waa in daawaynta CAR T-cell ay u baahan tahay faleebo keliya oo badanaa waxay u baahan tahay laba toddobaad oo keliya daryeelka bukaan-jiifka. Bukaannada qaba lymphoma non-Hodgkin iyo leukemia carruurta ee hadda la helay, dhanka kale, waxay caadi ahaan u baahan yihiin. chemotherapy ugu yaraan lix bilood ama ka badan.
Faa'iidooyinka daaweynta CAR T-cell, oo ah dawo nool, waxay sii jiri kartaa sanado badan. Haddi iyo marka ay soo noqodku dhacdo, unugyadu wali way awoodi doonaan inay aqoonsadaan oo ay beegsadaan unugyada kansarka sababtoo ah waxay ku noolaan karaan jidhka muddo dheer.
Inkasta oo macluumaadka uu weli soo korayo, 42% bukaannada lymphoma ee qaangaarka ah ee lagu sameeyay daawaynta CD19 CAR T-cell ayaa weli ku jira cafis 15 bilood ka dib. Lix bilood ka dib, saddex-meelood laba meel bukaannada qaba kansarka leukemia ee ba'an ee carruurta ayaa weli ku jiray cafis. Nasiib darro, bukaannadani waxay lahaayeen burooyin aad u daran kuwaas oo aan si guul leh loo daweyn iyadoo la adeegsanayo heerarka daryeelka dhaqameed.
Bukaanno noocee ah ayaa noqon doona kuwa qaata daawaynta unugga ee CAR-T?
Bukaanada da'doodu u dhaxayso 3 sano ilaa 70 sano waxay isku dayeen daawaynta CAR T-cell ee noocyada kala duwan ee kansarka dhiiga waxaana la ogaaday inay aad waxtar u leedahay. Xarumo badan ayaa sheegtey heerarka guusha ee in ka badan 80%. Musharaxa ugu wanagsan ee daawaynta unugyada CAR T-cell wakhtigan waa ilmo yar oo qaba lymfoblastic leukemia ba'an ama qof weyn oo qaba lymphoma B-cell oo daran kaas oo horey u lahaa laba xariiq oo daaweyn aan waxtar lahayn.
Ka hor dhamaadka 2017, ma jirin heer la aqbalay daryeelka bukaanka kuwaas oo horay u soo maray laba xariiq oo daawaynta ah iyada oo aan la kulmin cafis. Daawaynta kaliya ee FDA-ansixisay ee ilaa hadda la caddeeyey inay faa'iido weyn u leedahay bukaankan waa daawaynta CAR T-cell.
Sidee waxtar u leeyahay daawaynta unug ee CAR-T?
Daawaynta CAR T-cell ayaa aad waxtar u leh daaweynta noocyada kansarka dhiigga qaarkood, sida lymphoblastic leukemia ba'an (ALL) iyo lymphoma non-Hodgkin. Tijaabooyinka kiliinikada, heerka jawaab celinta ayaa aad u wanaagsanaa, bukaanno badan ayaa galay cafis buuxa. Xaaladaha qaarkood, dadka isku dayay dawo kasta waxay heleen cafis waara ama xataa daawooyin suurtagal ah.
Mid ka mid ah waxyaabaha ugu wanaagsan ee ku saabsan daaweynta CAR T-cell waa inay beegsato unugyada saxda ah. Qabayaasha CAR ee lagu daray unugyada T waxay heli karaan calaamado gaar ah unugyada kansarka. Tani waxay suurtogal ka dhigaysaa in la bixiyo daawaynta la beegsaday. Habkan la beegsanayo waxa ay wax u dhimaysaa unugyada caafimaadka qaba sida ugu yar ee suurtogalka ah waxana ay hoos u dhigtaa halista waxyeelooyinka ka yimaada daawaynta dhaqameed sida kiimoterabiga.
Laakiin waxaa muhiim ah in maskaxda lagu hayo in daawaynta CAR T-cell ay wali tahay aag cusub oo wali isbedelaysa. Cilmi-baarayaasha iyo takhaatiirta ayaa si adag u shaqeynaya si ay u xalliyaan dhibaatooyinka sida kharashka badan, suurtagalnimada waxyeellooyin halis ah, iyo xaqiiqda ah in ay u shaqeyso oo kaliya noocyada kansarka qaarkood.
Dhammaadkii, daawaynta unugga CAR T ee loo yaqaan 'multiple myeloma' ee Shiinaha ayaa muujisay inay tahay hab aad loogu guulaystay oo lagu daweeyo kansarkan. Inkasta oo ay tahay hab rajo leh oo awood leh, daraasado badan iyo tijaabooyin caafimaad ayaa loo baahan yahay si loo hagaajiyo loona helo habab cusub oo loo isticmaalo. Daaweynta CAR T-cell waxay bedeli kartaa sida loo daweeyo kansarka oo wax u roonaan kara dadka adduunka oo dhan haddii ay sii fiicnaanayso.
Shuruudaha ka mid noqoshada CAR T-Cell Therapy:
- Bukaanka qaba CD19+B-cell Lymphoma
- In ay da'doodu u dhaxayso 3 ilaa 75 sano
- Dhibcaha ECOG ≤2
- Dumarka awoodda dhalmada leh waa inay kaadiyaan uurkaTijaabada la qaaday oo la caddeeyey diidmada ka hor daaweynta. Dhammaan bukaannadu waxay ku heshiiyaan inay isticmaalaan habab la isku halayn karo oo ka hortagga uurka inta lagu jiro muddada tijaabada iyo ilaa la socodka wakhtiga ugu dambeeya.
Shuruudaha Ka-reebista ee CAR T-Cell Therapy:
- Dhiig kar intracranial ama miyir la'aan
- Fashilka neefsiga
- Faafin xinjirowga xididdada dhiigga
- Hematosepsis ama caabuq firfircoon oo aan la xakameynin
- Xakameyn la'aan sonkorow
CAR T-Cell Therapy Oo Ay Ansixisay USFDA
KYMRIAH
Unugyada B-unugyada leukemia ba'an oo soo noqnoqda ama soo noqnoqda
Heerka jawaabta oo dhammaystiran (CR): >90%
Beegsiga: CD19
Price: $ 475,000
Waqtiga ansixinta: Agoosto 30, 2017
YESCARTA
Soo noqoshada ama dib-u-soo-celinta waxay kala firdhisaa lymphoma unugga B-weyn, soo noqoshada ama dib-u-kicinta unugyada follicular
Heerka jawaab celinta dhamaystiran ee lymphoma non-Hodgkin (CR): 51%
Beegsiga: CD19
Price: $ 373,000
Waqtiga ansixinta: 2017 Oktoobar 18
TECARTUS
Soo noqoshada ama dib-u-celinta waxay faafisaa lymphoma weyn ee unugyada B
Limfoma unugga mantle ee heerka jawaab celinta oo dhameystiran (CR): 67%
Beegsiga: CD19
Price: $ 373,000
Waqtiga la ansixiyay: Oktoobar 18, 2017
BREYANZI
Soo noqoshada ama dib-u-celinta waxay faafisaa lymphoma weyn ee unugyada B
Heerka jawaabta oo dhammaystiran (CR): 54%
Beegsiga: CD19
Price: $ 410,300
Waqtiga la ansixiyay: Oktoobar 18, 2017
ABECMA
Dib-u-soo-kabashada ama dib-u-soo-celinta Multiple Myeloma
Heerka jawaabta oo dhammaystiran: 28%
Beegsiga: CD19
Price: $ 419,500
Waxaa la ansixiyay: Oktoobar 18, 2017
Waa maxay Saamaynnada Daawaynta Unugyada CAR-T?
Hoos waxaa ku yaal qaar ka mid ah waxyeelada daawaynta CAR T-cell.
- Cytokine release syndrome (CRS): Saamaynta ugu badan ee ugu badan ee suurtogalka ah ee daaweynta CAR T-cell waa cytokine release syndrome (CRS). Calaamadaha hargabka oo kale, oo ay ku jiraan qandho, daal, madax-xanuun, iyo murqo xanuun, waxaa keena wax-soo-saarka cytokines-ka T-ga ee la beddelay. Xaaladaha ba'an, CRS waxay keeni kartaa heerkul sare, hypotension, xubinta taranka, iyo xitaa cawaaqib halis ah.
- Sunta Neerfaha: Bukaanjiifka qaarkood waxaa laga yaabaa inay yeeshaan saameynaha neerfaha, kuwaas oo u dhexeeya darnaan laga bilaabo calaamado aan halis ahayn sida jahawareer khafiif ah iyo jahawareer ilaa kuwa ka sii daran sida suuxdin, delirium, iyo encephalopathy. Ka dib faleebada CAR T-cell, sunta neerfaha waxay badanaa dhacdaa usbuuca ugu horreeya.
- Cytopenia: Daawaynta CAR T-cell waxay keeni kartaa inay hoos u dhigto tirooyinka unugyada dhiigga, sida dhiig-yarida (tirada unugyada dhiigga cas oo hooseeya), neutropenia (tirada unugyada dhiigga cad oo hooseeya), iyo thrombocytopenia (tirada platelet hoose). Caabuqyada, dhiig-baxa, iyo daalka ayaa ka mid ah khataraha ay uga sii dari karto cytopenia.
- Caabuqyada: CAR T-cell therapy's xakamaynta unugyada difaaca jirka ee caafimaadka qaba waxay kordhisaa halista caabuqyada bakteeriyada, fayraska, iyo fungal. Si looga hortago caabuqyada, bukaanku waxa ay u baahan karaan in si dhow loo eego lana siiyo daawo ka hortag ah.
- Tumor Lysis Syndrome (TLS)Ka dib daaweynta CAR T-cell, waxaa suurtagal ah xaaladaha qaarkood in xaddi la taaban karo oo ka kooban unugyada lagu sii daayo dhiigga sababtoo ah dilka degdega ah ee unugyada burooyinka. Tani waxay keeni kartaa cillado dheef-shiid kiimikaad ah, sida potassium-ka xad-dhaafka ah, uric acid, iyo heerarka fosfateet, kuwaas oo dhaawici kara kelyaha oo sababi kara dhibaatooyin kale.
- Hypogammaglobulinemia: Daawaynta CAR T-cell waxay leedahay awood ay ku yarayso isku-darka unugyada difaaca jirka, taas oo keeni karta hypogammaglobulinemia. Tani waxay ka dhigi kartaa infekshannada soo noqnoqda inay u badan tahay waxayna wacdaa in la sii wado daawada beddelka unugyada.
- Sunta Xubinta: Daaweynta CAR T-cell waxay leedahay awood ay ku waxyeeleyso dhowr xubnood, oo ay ku jiraan wadnaha, sambabada, beerka, iyo kelyaha. Tani waxay u horseedi kartaa baaritaanada shaqada kelyaha ee aan caadiga ahayn, arrimaha neefsashada, arrimaha wadnaha, iyo baaritaanka shaqada beerka ee aan caadiga ahayn.
- Hemophagocytic lymphohistiocytosis (HLH): Cudur naadir ah laakiin suurtagal ah oo dilaa ah oo loo yaqaan hemophagocytic lymphohistiocytosis (HLH) ayaa ku soo bixi kara natiijada daawaynta CAR T-cell. Waxay ku lug leedahay firfircoonida xad-dhaafka ah ee unugyada difaaca jirka, taas oo keenta dhaawac halis ah xubnaha iyo bararka.
- Hypotension iyo Haysashada Dheecaannada: Natiijadu waxay tahay cytokines ay unugyada CAR T sii daayaan, bukaannada qaarkood waxaa laga yaabaa inay yeeshaan cadaadis dhiig oo hooseeya (hypotension) iyo xajinta dareeraha. Si wax looga qabto calaamadahan, tillaabooyin taageero ah oo ay ku jiraan dheecaannada xididka iyo dawooyinka ayaa loo baahan karaa.
- Xannaanada Labaad: Warbixinnada malignancies-ka labaad ee soo baxaya ka dib daaweynta CAR T-cell ayaa jira, inkastoo ay naadir yihiin. Cilmi baaris ayaa hadda lagu sameynayaa suurtagalnimada malignant-ka labaad iyo khataraha mustaqbalka fog.
Waxaa muhiim ah in la xasuusnaado in bukaan kastaa aanu yeelanayn waxyeellooyinkan iyo in qof walba heerka dareenkiisu uu kala duwanaan doono. Si loo yareeyo loona yareeyo saamaynta xun ee iman karta, kooxda caafimaadku waxay si dhow u baadhaan bukaanada ka hor, inta lagu jiro, iyo ka dib daawaynta CAR T-cell.
Waqtiga waqtiga
Hoos ka hubi wadarta wakhtiga loo baahan yahay si loo dhamaystiro habka daawaynta CAR T-Cell. Si kastaba ha ahaatee, waqtiga xaddidan wuxuu aad ugu xiran yahay masaafada shaybaarka u jiro isbitaalka diyaariyey CAR-yada.
- Imtixaan & imtixaan: hal usbuuc
- Daawaynta kahor & Ururinta T-Cell: hal usbuuc
- Diyaarinta T-Cell & soo celinta: laba ilaa saddex toddobaad
- Falanqaynta waxtarka 1aad: saddex toddobaad
- 2nd Waxtarka falanqaynta: saddex toddobaad.
Wadarta wakhtiga: 10-12 toddobaad
Sidee CancerFax kuugu caawin kartaa inaad hesho daawaynta unugyada CAR T?
Marka ay timaaddo xulashada lamaanaha ugu habboon safarkaaga daaweynta kansarka, CancerFax waxay u taagan tahay iftiin taageero iyo khibrad leh. Waayo-aragnimada badan ee bixinta daawaynta CAR T-cell, waxaanu aqoonsanahay muhiimada caafimaadkaaga iyo sida ay lagama maarmaanka u tahay helitaanka daryeel fiican. Waxa kala sooca CancerFax waa kooxdayada xirfadlayaasha daryeelka caafimaadka ee u heellan iyo naxariista kuwaas oo mudnaanta siiya wanaaggaaga inta lagu jiro habka daaweynta.
Waxaan aaminsanahay daawaynta gaarka ah sababtoo ah waxaan aqoonsannahay in bukaan kastaa uu gaar yahay oo u baahan yahay daryeel gaar ah. U hibeyntayada heer sare waxaa lagu muujiyay xulashada saxda ah ee khabiiro khibrad sare leh iyo la shaqeynta isbitaallo badan, anagoo hubinayna inaad hesho xulashooyinka ugu habboon baahiyahaaga adigoon u hurayn tayada. Tobankii sano ee la soo dhaafay, CancerFax waxay ahayd hage la aamini karo oo loogu talagalay bukaanada ka kala yimid wadamada 8, waxaanan ka go'an inaan kuu fidinno daryeel iyo taageero isku mid ah. La xidhiidh maanta si aad u hesho daawaynta unug ee CAR T ee ugu fiican Shiinaha.
CancerFax waxay la shaqaysay Kansarka ugu sarreeya iyo cusbitaallada dhiigga ee Shiinaha kuwaas oo ah xarumaha la ansixiyey ee maamulka daawaynta unug ee CAR T. Iyada oo ku saleysan bukaanka xaaladdiisa caafimaad iyo dhaqaale iyo u dhowaanshaha meesha uu u socdo, waxaan soo jeedineynaa isbitaalka ugu habboon.
Su'aalaha Badiya La Weydiiyo
Waa kuwee noocyada kansarka ee u qalma daaweynta CAR T-Cell ee Shiinaha?
Shiinaha, daawaynta CAR T-cell ayaa ugu horrayn la oggolaaday waxaana loo isticmaalaa daawaynta cudurrada dhiig-baxa, sida lymphoma, leukemia, iyo myeloma.
Iyadoo ay jiraan tijaabooyin caafimaad iyo dadaal cilmi-baaris oo sahaminta daaweynta CAR T-cell ee burooyinka adag, horumarka aaggan ayaa ahaa mid gaabis ah marka loo eego cudurrada dhiig-baxa.
Sida ku cad macluumaadka la heli karo, CAR T-cell daawaynta ee burooyinka adag waxay ku xisaabtamaan kaliya 9% wadarta daawaynta CAR T-cell ee lagu sameeyay Shiinaha.
Sidee buu waxtar u yahay daawaynta unugyada CAR T ee Shiinaha marka la barbar dhigo daawaynta kale?
Waxtarka daaweynta chimeric antigen reseptor T-cell (CAR-T) ee Shiinaha ayaa la barbardhigay daawaynta beddelka ah iyada oo loo marayo tijaabooyin caafimaad oo ballaaran iyo cilmi baaris. Laga bilaabo 2022, Shiinuhu wuxuu leeyahay tiro ka badan oo daraasadaha caafimaad ee CAR-T marka loo eego Maraykanka, gaar ahaan cudurrada dhiigbaxa. Laba daawaynta CAR-T, axicabtagene ciloleucel (Yescarta) iyo relmacabtagene autoleucel (Carteyva), ayaa lagu ansixiyay Shiinaha Maamulka Alaabooyinka Caafimaadka Qaranka (NMPA).
Daaweynta CAR-T ee Shiinaha waxay muujisay waxtarka cudurrada dhiigga ee kala duwan, oo ay ku jiraan B-cell lymphoblastic leukemia (ALL), lymphoma, iyo multi myeloma (MM). Si kastaba ha ahaatee, caqabadaha ayaa weli ah, sida qiimaha sarreeya, habka wax soo saarka waqti-qaadashada, iyo dhacdooyinka xun ee la xiriira difaaca. Si wax looga qabto arrimahan, cilmi-baarayaasha Shiinaha ayaa soo saaraya xeelado lagu wanaajinayo daaweynta CAR-T, oo ay ku jiraan horumarinta alaabada CAR-T ee allogeneic iyo isticmaalka meelo kale oo kharash-bixineed ah.
Marka la soo koobo, daawaynta CAR-T ee Shiinaha ayaa muujisay natiijooyin rajo leh oo ku saabsan malignancies hematologic, oo leh tiro badan oo tijaabo caafimaad ah marka loo eego Maraykanka. Si kastaba ha ahaatee, caqabadaha ayaa weli ah, waxaana loo baahan yahay cilmi-baaris dheeraad ah si kor loogu qaado daaweynta loona ballaariyo isticmaalkeeda burooyinka adag.
Waa maxay waxyeelooyinka lagu arkay daawaynta unug ee CAR T ee Shiinaha?
Shiinaha, waxyeellooyinka lagu arkay daaweynta CAR T-cell waxaa ka mid ah:
-Cytokine release syndrome (CRS)
- Neurotoxicity ama dhacdooyinka neerfaha
- Caabuqyada, gaar ahaan caabuqyada fayraska
- Unugyada B oo yaraada (aplasia)
- Hypogammaglobulinemia
- Cytopenia
Waxyeellooyinkan soo raaca maaha kuwo u gaar ah Shiinaha laakiin waxay ku badan yihiin daawaynta unugyada CAR T-cell adduunka oo dhan. Maareynta iyo ka hortagga dhibaatooyinkan soo raaca ayaa muhiim u ah xaqiijinta badbaadada bukaanka iyo wanaajinta natiijooyinka daaweynta.
Intee ayuu qaali ku yahay daawaynta CAR T gudaha Shiinaha?
Iibka jumlada ee daawaynta unugyada CAR-T ee Shiinaha waxay guud ahaan ku dhow yihiin Shiinaha Yuan (CNY) 1,200,000, taas oo u dhiganta ku dhawaad US$170,000. Waxtarka waxtarka leh ee daaweynta unugyada CAR-T ee Shiinaha way kala duwan tahay iyadoo ku xiran daawaynta gaarka ah iyo xaaladda bukaanka. Tusaale ahaan, saamiga korodhka waxtarka waxtarka leh (ICER) ee Axicabtagene ciloleucel (Axi-cel) oo ka soo horjeeda heerka daryeelka (SOC) ee bukaanada qaba lymphoma weyn ee B-cell (DLBCL) ee goobta-labaad (2L) waxay ahayd qiyaastii. CNY 363,977 sanad-nololeed tayo la isku hagaajiyay (QALY). Si kastaba ha ahaatee, daawayntan looma tixgalinayo inay wax ku ool u yihiin goob kasta oo khadka ah oo loogu talagalay bukaannada DLBCL ee Ururka Caafimaadka Adduunka (WHO) - waxay ku taliyeen rabitaanka-bixinta heerka. Hoos u dhigista qiimaha daawaynta CAR-T waa habka ugu muhiimsan ee hoos loogu dhigo ICERs iyo hubinta in kharashyada daawadu ay la siman yihiin faa'iidooyinka caafimaadka bukaanka.
Ma jiraan tijaabooyin caafimaad oo socda oo loogu talagalay daawaynta CAR-T gudaha Shiinaha?
Haa, waxaa jira tijaabooyin caafimaad oo socda oo loogu talagalay daaweynta unugyada CAR-T ee Shiinaha. Laga bilaabo Janaayo 2024 waxaa jira in ka badan 700 oo tijaabo caafimaad oo socda oo loogu talagalay daawaynta unugyada CAR T ee Shiinaha. Shiinuhu waxa uu noqday dalka ugu diiwaan gashan tijaabooyinka CAR-T, tanina way sii socotay ilaa wakhtigaas. Dawladda Shiinaha ayaa si weyn u maalgelisay cilmi-baarista CAR-T, waddankuna wuxuu leeyahay tiro badan oo tijaabo caafimaad ah iyo cilmi-baaris aasaasi ah oo arrintan ku saabsan. Tijaabooyinku waxay kordhiyaan baaxadda daawaynta laga soo bilaabo malignancies hematologic ilaa burooyinka sloid iyo xanuunada kale qaarkood.
Sideen ku helaa cisbitaalka ama dhakhtarka ugu fiican ee bixiya daawaynta CAR T-cell gudaha Shiinaha?
CancerFax waxay fahansan tahay muhiimada ay leedahay doorashada xarunta ugu fiican iyo takhasuska daaweynta unugyada CAR T ee Shiinaha. Adeegeena u heellan wuxuu diiradda saarayaa isku xirka dadka leh daryeelka kansarka ugu fiican oo qiimo jaban ah. Waxaan si gaar ah ula shaqaynaa cusbitaalada ugu sareeya ee dhiigbaxa iyo kansarka ee Shiinaha kuwaas oo helay ogolaanshaha maaraynta daawaynta unugyada CAR T. Waxaan ka caawinnaa bukaanada inay doortaan ikhtiyaarka ugu fiican iyadoo loo eegayo baahiyahooda iyo shuruudaha.
Waa maxay shuruudaha lagu tixgalinayo in lagu daweyn karo CAR T-CELL gudaha Shiinaha?
Shuruudaha u-qalmitaanka daaweynta unugyada CAR T ee Shiinaha way kala duwan yihiin iyadoo ku xiran daawaynta gaarka ah iyo xaaladda bukaanka. Guud ahaan, bukaannada qaba cudurrada dhiig-baxa, sida lymphoma, leukemia, iyo myeloma, ayaa ah musharaxiinta ugu muhiimsan ee daaweynta unugyada CAR T ee Shiinaha.
Bukaan-socodka waa in la xaqiijiyo ogaanshaha nooca kansarka ee gaarka ah oo ay ku guuldareysteen inay ka jawaabaan daawaynta caadiga ah, sida kiimoterabiga ama daaweynta shucaaca.
Intaa waxaa dheer, bukaanku waa inay buuxiyaan shuruudaha caafimaadka qaarkood, sida inay leeyihiin hawl xubin oo ku filan oo aan lahayn caabuq firfircoon ama xaalado caafimaad oo kale oo halis ah oo faragelin kara daaweynta. Shuruudaha u-qalmitaanka ee tijaabo caafimaad kasta way kala duwanaan kartaa, bukaannadu waa inay buuxiyaan shuruudaha gaarka ah ee tijaabada si ay uga qaybqaataan.
Si loogu tixgeliyo u-qalmitaanka daaweynta unugyada CAR T ee Shiinaha, bukaanku waa inay buuxiyaan shuruudaha qaarkood. Shuruudahan waxaa ka mid ah CD19+ B-cell Lymphoma oo leh ugu yaraan laba jeer oo isku darka kemotherabi hore, da'da u dhaxaysa 3 ilaa 75 sano, iyo dhibcaha ECOG ee ≤2. Intaa waxaa dheer, bukaanada dheddigga ah ee awoodda taranka leh, baaritaanka uurka waa in la sameeyaa oo la xaqiijiyaa diidmo ka hor inta aan daawaynta bilaabmin. Intaa waxaa dheer, dhammaan bukaanada waa inay ku heshiiyaan inay isticmaalaan hab la isku halayn karo oo ka hortag ah inta lagu jiro tijaabada iyo ilaa dabagalka ugu dambeeya.
Ma jiraan xeerar ama xannibaadyo loogu talagalay bukaannada ajnabiga ah ee u safraya Shiinaha si ay u helaan daawaynta unugyada CAR T?
Ma jiraan xayiraad noocaas ah oo loogu talagalay bukaannada ajnabiga ah. Si kastaba ha ahaatee, helitaanka daawaynta ugu fiican Shiinaha waxay u baahan tahay ogolaansho laga helo maamulka caafimaadka iyo fiisaha caafimaadka.
Intee ugu dhakhsaha badan ayaan filan karnaa inaan ka aragno natiijooyinka daawaynta daawaynta unugyada T-Cell ee Shiinaha?
Waqtiga loogu talagalay bukaannada si ay u arkaan natiijooyinka daaweynta unugyada CAR T ee Shiinaha way kala duwanaan kartaa. Caadi ahaan, skaannada waxaa la sameeyaa 2-3 toddobaad ka dib si loo hubiyo saameynta daaweynta unugyada CAR T. Daawaynta unugga CAR T waxay guulo la taaban karo ka gaadhay daawaynta malignant-ka dhiigga, iyo Shiinuhu wuxuu noqday waddan hormuud u ah tijaabooyinka daawaynta ee CAR T. Si kastaba ha ahaatee, waxaa muhiim ah in la ogaado in natiijooyinka daaweynta unugyada CAR T ay ku kala duwanaan karaan bukaan kasta, iyo waqtiga gaarka ah ee natiijooyinka la arki karo waxay ku xiran tahay arrimo ay ka mid yihiin xaaladda bukaanka, nooca kansarka ee la daweynayo, iyo CAR T gaarka ah. daawaynta unugga oo la isticmaalayo. Iyadoo daawaynta ay soo bandhigtay saameyno caafimaad oo cajiib ah, oo ay ku jiraan heerka jawaab celinta guud ee sarreeya, waqtiga saxda ah ee marka bukaanku filan karo inuu arko natiijooyinka waxaa laga yaabaa in aan si caalami ah loo qeexin oo waxay ku kala duwanaan kartaa shakhsi ilaa shakhsi. Sidaa darteed, waxaa lagu talinayaa in bukaannada ay la tashadaan bixiyaashooda daryeelka caafimaadka iyo baarayaasha tijaabada caafimaad si ay u helaan macluumaad gaar ah oo ku saabsan waqtiga la filayo si loo arko natiijooyinka daaweynta unugyada CAR T.
Ma loo baahan yahay daawaynta daba-galka muddada-dheer ama la socodka bukaannada ku qaatay daawaynta CAR T-Cell ee Shiinaha?
Haa, daawaynta daba-galka muddada-dheer ama la socodka ayaa looga baahan yahay bukaannada ku qaatay daawaynta unugyada CAR T gudaha Shiinaha. Daawaynta unugga CAR T waxay soo bandhigtay saameyno caafimaad oo cajiib ah oo lagu daweynayo malignancies hematological, laakiin waxay sidoo kale yeelan kartaa saameynaha soo raaca, sida cytokine release syndrome (CRS) iyo neurotoxicity.
Sidaa darteed, bukaannada qaatay daawaynta unugga CAR T waxay u baahan yihiin la socosho dhow oo ku saabsan waxyeellooyinka iman kara iyo dabagal dheer si loo qiimeeyo waarta jawaabta iyo soo noqoshada suurtagalka ah ee kansarka. Muddada dabagalku way kala duwanaan kartaa iyadoo ku xidhan daawaynta gaarka ah iyo xaalada bukaanka, laakiin caadi ahaan waxay ku lug leedahay baadhitaano joogto ah iyo baadhitaano sawireed si loola socdo caafimaadka bukaanka loona ogaado wax kasta oo soo noqnoqon kara kansarka.
Intaa waxaa dheer, bukaanku waxay u baahan karaan daryeel taageero, sida dawooyin lagu maareeyo waxyeelada ama daawaynta dheeraadka ah haddii kansarku soo noqdo.
Suurtagal ma tahay in lagu daro daawaynta unugyada CAR T iyo daawaynta kale sida kiimoterabiga, shucaaca, ama beerista dhuuxa lafta?
Haa, waa suurtogal in lagu daro daawaynta unugyada CAR T iyo daawaynta kale sida kiimoterabiga, shucaaca, ama beerista dhuuxa lafta. Waxaa jira xiisaha sii kordhaya ee isku darka daaweynta unugyada CAR T iyo wakiilada kale ee ka hortagga kansarka si loo wanaajiyo natiijooyinka daaweynta, gaar ahaan marka la eego macnaha cudurrada dhiig-baxa. Tusaale ahaan, myeloma, isku-darka waxaa ka mid noqon kara daaweynta caadiga ah ee myeloma ee la bixiyo ka dib faleebo CAR T-cell ah oo ah istiraatiijiyad dayactir ah.
Intaa waxaa dheer, isku darka daaweynta shucaaca ee daaweynta unugyada CAR-T waxay muujisay saameyn rajo leh oo kor loogu qaadayo difaac gaar ah iyo abuurista buro microenvironment oo aad u wanaagsan oo loogu talagalay unugyada CAR-T ee burooyinka adag.
Intaa waxaa dheer, isku-darka daaweynta kemotherabi iyo daaweynta unugyada CAR-T ayaa loo sahamiyay sidii istaraatiijiyad looga gudbi karo caqabadaha ku jira daaweynta unugyada CAR-T oo ay bixiso saameyn isku-dhafan, gaar ahaan daaweynta burooyinka adag. Hababkan isku-dhafka ah waxay ujeedadoodu tahay in la wanaajiyo badbaadada iyo waxtarka daaweynta unugyada CAR-T iyadoo wax laga beddelayo buro microenvironment, hagaajinta qaab-dhismeedka CAR, iyo suurtogalnimada in la beegsado antigens badan.
Waa maxay horumarka ama horumarka ka dhacaya CAR T-cell therapy cilmi gudaha Shiinaha?
Shiinaha, cilmi-baarista daaweynta unugyada CAR T ayaa si degdeg ah u kobcaysa, iyada oo waddanku leeyahay tijaabooyinka bukaan-socodka ee ugu badan ee CAR T tan iyo 2017. Dawladda Shiinaha ayaa si weyn u maalgelisay daaweynta unugyada CAR T, waddankuna wuxuu leeyahay tiro badan oo tijaabo caafimaad ah iyo aasaaska aasaasiga ah. cilmi baaris ku saabsan arrintan. Daawaynta unugyada CAR T ayaa loo oggolaaday daawaynta cudurrada dhiig-baxa, sida faafinta weyn ee B-cell lymphoma (DLBCL).
Cilmi-baarayaasha Shiinaha waxay sahamiyaan xeelado kala duwan si ay u wanaajiyaan daaweynta unugyada CAR T, oo ay ku jiraan horumarinta dhismayaasha cusub ee CAR, daaweynta isku dhafan ee daaweynta kale, iyo isticmaalka unugyada CAR T ee burooyinka adag. Si kastaba ha ahaatee, caqabadaha ayaa weli ah, sida kakanaanta wax soo saarka iyo maamulka, kharashka badan ee daaweynta, iyo baahida loo qabo tijaabooyin caafimaad oo macquul ah iyo asalka ah.
In kasta oo ay carqaladeeyeen tijaabooyinka bukaan-socodka ee cudurka faafa ee COVID-19, cilmi-baaris ayaa ka sii socota Shiinaha, iyada oo hay'adda sharciyeynta ee waddanka, Maamulka Waxsoosaarka Caafimaadka Qaranka (NMPA), ay oggolaatay kaliya laba daawaynta CAR T sida macluumaadka ugu dambeeyay ee la heli karo.
Waa maxay tillaabooyinka guud ee ku lug leh safarka Shiinaha ee daawaynta CAR-T-cell?
Tallaabooyinka guud ee ku lug leh safarka Shiinaha ee daaweynta unugyada CAR T way kala duwanaan karaan iyadoo ku xiran cisbitaalka gaarka ah ama xarunta daawaynta. Si kastaba ha ahaatee, talaabooyinka guud qaarkood waxaa ka mid noqon kara:
1. Baadhista cisbitaalada ama xarumaha daawaynta ee Shiinaha oo bixiya daawaynta unugyada CAR T iyo xulashada mid daboolaya baahiyahaaga.
2. La xiriirida cisbitaalka ama xarunta daawaynta si aad wax uga waydiiso habka daawaynta, oo ay ku jiraan kharashka, shuruudaha u-qalmitaanka, iyo dukumeenti kasta oo lagama maarmaan ah.
3. Helitaanka gudbinta bixiyaha xanaanada caafimaadkaaga iyo bixinta xogta caafimaadka isbitaalka ama xarunta daawaynta.
4. Codsashada fiisaha caafimaadka si loogu safro Shiinaha si loogu daweeyo.
5. Diyaarinta safarka iyo hoyga naftaada iyo xubnaha qoyska ee weheliya.
6. In lagu sameeyo qiimayn iyo baadhis caafimaad marka la yimaado cusbitaalka ama xarunta daawaynta.
7. Helitaanka daawaynta unugga CAR T iyo qaadashada daryeel kasta oo lagama maarmaan ah.
8. Ku soo noqoshada guriga iyo sii wadida daryeelka iyo la socodka muddada dheer.
Waxaa muhiim ah in la ogaado in tillaabooyinka gaarka ah ee ku lug leh safarka Shiinaha ee daaweynta unugyada CAR T ay kala duwanaan karaan iyadoo ku xiran isbitaalka ama xarunta daweynta iyo xaaladaha gaarka ah ee bukaanka. Waxaa lagu talinayaa in bukaanku la tashado bixiyaashooda daryeelka caafimaadka iyo isbitaalka ama xarunta daawaynta macluumaad gaar ah oo ku saabsan habka daaweynta iyo shuruudaha safarka.
CancerFax ayaa kaa ilaalinaysa dhammaan tillaabooyinkan si aad diiradda u saarto daawaynta inta aanu daryeeleyno dhammaan waxyaabaha kale.
Waa maxay heerka guusha CAR T ee Shiinaha?
Daaweynta CAR T-cell waxay muujisay natiijooyin rajo leh oo ku saabsan daaweynta kansarka dhiigga ee Shiinaha. Laga bilaabo Janaayo 2024, Shiinuhu wuxuu lahaa tijaabooyinka caafimaad ee ugu joogtada ah adduunka ee tijaabinta daaweynta CAR T-cell, iyada oo 337 diiradda lagu saaray kansarka dhiigga iyo 111 ee burooyinka adag. Daaweynta CAR T-cell waxay hoos u dhigtay burooyinka 75.9% bukaannada lymfoma kuwaas oo cudurkoodu soo noqday ka dib daawayntii hore ee lagu guuldareystay. In ka badan kala badh (51.7%) bukaanada ayaan lahayn burooyin la ogaan karo daawaynta ka dib. Hal sano ka dib, 76.8% bukaannada lymphoma ayaa noolaaday. Shiinaha ayaa ansixiyay laba daawaynta CAR T-cell oo lagu magacaabo FKC876 iyo Carteyva oo loogu talagalay daawaynta kansarka. Shiinaha ayaa hogaaminaya cilmi-baarista caalamiga ah iyo horumarinta daaweynta CAR T-cell.